ArticleJournal of cancer research and clinical oncology2009
Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome.
Article in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Pooled it
- DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients.International journal of oncology · 2013Trial
- Review
- Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients.Translational lung cancer research · 2019Article
- Clinicopathological and prognostic significance of circulating tumor cells in patients with esophageal cancer: a meta-analysis.OncoTargets and therapy · 2018Review
- The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers.Frontiers in oncology · 2018Review
- Plasma DNA methylation of p16 and shp1 in patients with B cell non-Hodgkin lymphoma.International journal of clinical oncology · 2017Article
- Epigenetic Biomarkers in Colorectal Cancer.Molecular diagnosis & therapy · 2017Review
- Liquid biopsy and NSCLC.Lung cancer management · 2016Review
- Methylated circulating tumor DNA in blood: power in cancer prognosis and response.Endocrine-related cancer · 2016Review
- Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Review
- DRP-1, ezrin and E-cadherin expression and the association with esophageal squamous cell carcinoma.Oncology letters · 2014Article
- Incidence and prognostic value of multiple gene promoter methylations in gliomas.Journal of neuro-oncology · 2014Article
- The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.International journal of molecular sciences · 2013Review
- Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.Cellular oncology (Dordrecht, Netherlands) · 2013Article
- Reduced expression levels of the death-associated protein kinase and E-cadherin are correlated with the development of esophageal squamous cell carcinoma.Experimental and therapeutic medicine · 2013Article
- Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.Cancer letters · 2012Article
- Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.International journal of clinical and experimental pathology · 2012Review
- Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications.Journal of oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDeath-associated protein kinase (DAPK) and adenomatous polyposis coli gene (APC) have been recently shown to be associated with outcome in patients with esophageal carcinoma, especially adenocarcinoma. We wanted to validate the correlation of these two markers with outcome by detecting methylated DNA sequences in peripheral blood.
methodsCirculating cell-free DNA extracted from blood plasma of 59 patients with esophageal cancer was analyzed before and after surgical resection by quantitative real-time methylation-specific RT-PCR (TaqMan) assays.
resultsThirty-six of 59 patients (61.0%) with esophageal cancer had detectable levels of methylated DAPK or APC promoter DNA and preoperative detection was significantly associated with an unfavorable prognosis as revealed by multivariate Cox proportional hazards regression analysis [Exp(b) = 4.578; P = 0.01]. The combination of both markers significantly increased sensitivity and specificity for discriminating between short (<2.5 years) and long survivors (P = 0.04, ROC curve analysis). Postoperative APC detection was significantly different if residual tumor was apparent (P = 0.03).
conclusionsPreoperative measurement of methylated DAPK and APC promoter DNA in peripheral blood may contribute to better estimate postoperative survival chances of patients with esophageal carcinoma, especially adenocarcinoma. The postoperative detection of methylated APC in peripheral blood might provide crucial information on apparent residual tumor and might be used as a "molecular" R0-Marker in addition to the pathologic examination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.